Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCD FLAMSA-RIC allogeneic stem cell transplantation in elderly AML or high-risk MDS
2012-004421-24Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Apr 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine, amsacrine and cytarabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Leiden University Medical Center. Primary endpoint: Number of patients eligible for donor lymphocyte infusion at 6 months after transplantation. Started Apr 2014; status: active.
02
Drugs
fludarabineamsacrinecytarabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2012-004421-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004421-24.